EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia

Seo-Yeon Ahn, TaeHyung Kim, Mihee Kim, Ga-Young Song, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Mi Yeon Kim, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon und 6 weitere

Cancer Research and Treatment · 15.07.2023 · 55 (3) · 1011-1022

DOI: 10.4143/crt.2022.1407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.07.2023. Verfasst von Seo-Yeon Ahn und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea. Hauptthemen laut MEDLINE: CCAAT-Enhancer-Binding Protein-alpha, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We evaluated the characteristics of CCAAT/enhancer-binding protein α (CEBPA) mutations and the significance of a basic leucine zipper in-frame mutation (bZIPin-f) of CEBPA in patients with acute myeloid leukemia with a normal karyotype.Materials and Methods Based on updated knowledge of CEBPA mutations, we conducted next-generation sequencing analyses in a previously established real-world cohort.

Results

Among 78 of a total of 395 patients (19.7%), 50 had bZIPin-f CEBPA, and 28 had non-bZIPin-f CEBPA. In the multivariate analysis, patients with NPM1mut, those with bZIPin-f CEBPA, and those who underwent allogeneic hematopoietic cell transplantation (allo-HCT) had favorable overall survival (OS), but FLT3-ITDmut was a poor prognostic indicator. For relapse-free survival (RFS) and cumulative incidence of relapse, bZIPin-f CEBPA, and allo-HCT were associated with favorable outcomes; FLT3-ITDpos was associated with worse outcomes. In the CEBPA double-mutated group (CEBPAdm), bZIPin-f CEBPA was associated with superior outcomes in terms of OS (p=0.007) and RFS (p=0.007) compared with non-bZIPin-f CEBPA. Of 50 patients with bZIPin-f CEBPA, 36 patients had at least one mutation. When grouped by the presence of mutations in chromatic/DNA modifiers (C), cohesion complex (C), and splicing genes (S) (CCS mutations), CCS-mutated bZIPin-f CEBPA was associated with poor OS (p=0.044; hazard ratio [HR], 2.419) and a trend in inferior RFS (p=0.186; HR, 1.838).

Conclusion

Only bZIPin-f CEBPA was associated with favorable outcomes in patients with CEBPAdm. However, some mutations accompanying bZIPin-f CEBPA showed inferior OS; thus, further studies with larger numbers of patients are required for clear conclusions of the significance of bZIPin-f CEBPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CCAAT-Enhancer-Binding Protein-alphaLeukemia, Myeloid, AcuteHumansClinical RelevanceDisease-Free SurvivalNucleophosminMutationPrognosisKaryotypeCCAAT-Enhancer-Binding Proteins

Stichwörter der Autor:innen

AcuteAllogeneic transplantationCEBPALeukemiaMyeloidNext-generation sequencing

Substanzen

CCAAT-Enhancer-Binding Protein-alphaNucleophosminCEBPA protein, humanCCAAT-Enhancer-Binding Proteins

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
  • The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
  • Department of Computer Science, University of Toronto, Toronto, Canada.
  • Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Korea.
  • Division of Hematology-Oncology, Samsung Medical Center, Seoul, Korea.
  • Department of Hematology, Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Ministry of Health and Welfare
  • Chonnam National University Hospital
  • Chonnam National University Hwasun Hospital Institute for Biomedical Science

Zitieren

APA

Ahn, S. Y., Kim, T., Kim, M., Song, G. Y., Jung, S. H., Yang, D. H., Lee, J. J., Kim, M. Y., Jung, C. W., Jang, J. H., Kim, H. J., Moon, J. H., Sohn, S. K., Won, J. H., Kim, S. H., Kim, H. J., Ahn, J. S., & Kim, D. D. H. (2023). Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia. Cancer Research and Treatment, 55(3), 1011-1022. https://doi.org/10.4143/crt.2022.1407

Vancouver

Ahn SY, Kim T, Kim M, Song GY, Jung SH, Yang DH, et al. Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia. Cancer Research and Treatment. 2023;55(3):1011-1022. doi:10.4143/crt.2022.1407

BibTeX
@article{Ahn2023,
  author = {Ahn, Seo-Yeon and Kim, TaeHyung and Kim, Mihee and Song, Ga-Young and Jung, Sung-Hoon and Yang, Deok-Hwan and Lee, Je-Jung and Kim, Mi Yeon and Jung, Chul Won and Jang, Jun-Ho and Kim, Hee Je and Moon, Joon Ho and Sohn, Sang Kyun and Won, Jong-Ho and Kim, Sung-Hyun and Kim, Hyeoung-Joon and Ahn, Jae-Sook and Kim, Dennis Dong Hwan},
  title = {Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia},
  journal = {Cancer Research and Treatment},
  year = {2023},
  volume = {55},
  number = {3},
  pages = {1011--1022},
  doi = {10.4143/crt.2022.1407}
}
Kostenlos starten →